Porcine Vaccines Market Worldwide Prospects 2019, Industry Share, Crucial Players, Size Estimation, Competitive Breakdown and Regional Forecast 2026
Vaccines have been one of the most vital medications for disease control in both humans and animals. Under veterinary pharmaceuticals, vaccination is considered as a windfall for maintaining animal health by preventing spread of several endemic diseases. Such diseases which can be endemic are porcine reproductive and respiratory virus (PRRSV), swine influenza, diarrhea, porcine circovirus-associated disease (PCVAD). Furthermore, infectious disease such as cholera, high fever, foot, and mouth diseases in swine have been significantly eliminated in North America through immunization.
For more information, Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1685
Infection of swine with porcine parvovirus (PPV) has been reported around the globe, which may lead to reproductive failure in swine or cutaneous lesions in piglets. In 1994, the first vaccine for the prevention of porcine reproductive and respiratory syndrome (PRRS) was registered and since then a number of additional vaccines (comprising either attenuated or inactivated PRRSV) have been developed in the U.S. and Europe. Each vaccine include a different strain of the virus of either the North American or European genotype. According to an article published in NCBI, 2017, around 70% of producers of pig farming are small farmers with farms fewer than 50 pigs each, and hygienic measures and feed of the pigs is not controlled, which is propelling demand of porcine vaccines market.
Some commercially available (non-autogenous) porcine reproductive and respiratory syndrome (PRRS) vaccines are:
|Current Name||Type||Virus Strain Origin||Manufacturer|
|Suvaxyn-PRRS2||Inactivated||European||Fort Dodge Veterinaria SA|
|Ingelvac PRRS MLV3||Attenuated||North American||Boehringer Ingelheim|
|Ingelvac PRRS ATP||Attenuated||North American||Boehringer Ingelheim|
|Suipravac- PRRS||Inactivated||European||Hipra Laboratories|
Source: Journal of Swine Health and Production
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1685
Global Porcine Vaccines Market – Driver
Growing demand for gelatin is expected to drive growth of the global porcine vaccines market during the forecast period. Gelatin is used as stabilizing agent to ensure safety and efficacy if vaccine during storage. Furthermore, growing consumption of meat, milk, eggs, & animal protein coupled with rising concerns related increasing incidences of zoonotic diseases are expected to propel the growth of the global porcine vaccines market in the near future. For instance, Vietnam is the third country in the world by per-capita pig meat consumption, with an average of 29.14 kilos of meat consumed in 2015.
Moreover, increasing number of biotechnology companies, research institutes that are engaged in research and development activities of porcine vaccines coupled with proactive government initiatives for funding agriculture and animal husbandry sector are expected to drive the global porcine vaccines market growth. For instance, in 2014, the International Livestock Research Institute (ILRI) initiated a program to raise pig farming more efficiently. These program featured three factors to support pig farming, which include improving feeding through public-private partnerships, improving the breeding and housing of village pigs, and controlling classical swine fever, a highly contagious and potentially fatal disease of pigs. Therefore, all these initiatives are expected to augment growth of the market over the forecast period.
Furthermore, researchers are focused on developing vaccines for major diseases such as African Swine Flu (ASF), which is expected to drive the market growth in the near future. ASF is present in sub-Saharan Africa, Russian Federation, Sardinia, and some of the Eastern European Countries. Moreover, there is no vaccine till today for this devastating disease. However, in 2017, researchers in the U.S. and Australia unveiled genetic data that could help in developing a vaccine for ASF, which is driving growth of the global porcine vaccines market.
Market Dynamics- Restraint
However, the high cost of maintaining, handling, and storage of these vaccines is expected to hinder the global porcine vaccine market growth in the near future.
Global Porcine Vaccines Market – Regional Analysis
On the basis of geography, the global porcine vaccines market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America accounts for the largest market share in the global porcine vaccines market. This is owing to highly organized farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners. Moreover, ease in export and import permits among contract manufacturers or distributer firms and low estimated cost of products are expected drive growth the global porcine vaccine market in Europe. For instance, in 2016, a UK-based Cranswick Foods company initiated a project to set up pork processing plant in Punjab, which would act as a catalyst to accelerate the process of value addition in animal husbandry sector and give boost to the farm diversification, providing high quality pork to the consumers across the state. Asia Pacific market (including Vietnam, the Philippines, etc.) is estimated to register a significant CAGR during the forecast period as these countries have large consumption of pig meat, which in turn is propelling growth of the market.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/porcine-vaccines-market-1685
Global Porcine Vaccines Market – Competitive Landscape
Key players are introducing porcine vaccines with new features such as such as DNA vaccines, recombinant vaccines, and conjugate vaccines. This advanced vaccines are expected to improve the efficiency and effectively of swine production practices with reduction in overall vaccination cost.
Major players operating in global porcine vaccines market include Bayer AG, Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A, and Vetoquinol, Zoetis, Inc.
Global Porcine Vaccines Market – Taxonomy
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- DNA Vaccines
By Disease Indication
- Swine Influenza
- Bordatella Rhinitis
- Porcine Reproductive and Respiratory Virus (PRRSV)
- Porcine Circovirus Associated Disease (PCVAD)
By End User
- Veterinary Hospitals
- Hog/Pig Production Farm
- North America
- Latin America
- Asia Pacific
- Middle East
Have a Look at Related Research Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire